Genosco specializes in medicinal chemistry, structural and computational drug discovery design, cell biology, pharmacology, and drug metabolism. They use a highly targeted approach with expertise in selective kinase inhibitors to discover and develop new drugs for patients. Their proprietary G-SMART™ platform enables the discovery and optimization of highly selective compounds. They have a strong portfolio of multiple independent and partnered pipelines, including their most advanced pipeline, Lazertinib, which is currently undergoing a phase 3 global clinical trial by Janssen and is also available in Korea for patients with EGFRm+ non-small cell lung cancer. Their interdisciplinary team consists of scientists with deep expertise in various fields, all working towards the shared mission of developing world-class precision medicine to improve people's lives.